Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096538 · ClinicalTrials.gov registry record · NA
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
A NA study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00096538: Completed NA study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00096538 is a NA study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096538, a NA study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts against many types of herpesviruses and may be an effective treatment for Kaposi's sarcoma. PURPOSE: This clinical trial is studying how well valganciclovir works in treating patients with classic non-HIV-associated Kaposi's sarcoma.
Interventions
- DRUG valganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2004-04 |
| Est. Completion | 2008-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096538
The ClinicalTrials.gov registry entry for NCT00096538 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which valganciclovir is the first listed.
NCT00096538 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096538 about?
NCT00096538 is a clinical study titled "Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma". RATIONALE: Herpesvirus is found in the lesions of most patients with Kaposi's sarcoma, and may have a role in causing Kaposi's sarcoma. Valganciclovir is an antiviral drug that acts against many types of herpesviruses and may be an effective treatment for Kaposi's sarcoma. PURPOSE: This clinical tr...
What is the current status of trial NCT00096538?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2004-04. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00096538?
The interventions under investigation include: valganciclovir (DRUG).
Who is sponsoring clinical trial NCT00096538?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.